Innospec Inc

Despite a healthy Stage 2 advancing regime marked by higher highs and higher lows, price is currently extended above rising short-term EMAs and in extreme overbought territory, reducing immediate entry appeal. The medium-term bias remains bullish, but short-term timing is unfavorable. We will stalk for pullbacks into rising 9/20 EMAs or the 50 DMA, seeking support and renewed momentum before engaging.

• ↑Fuel specialties segment revenue grew to $181.6M, +7% YoY with strong volumes and pricing.
• ↑Repurchased 90,000 shares for $6.2M and increased dividend 10% to $0.92/share.
• ↓Performance chemicals volumes declined 9% due to winter‐storm shutdowns, squeezing segment margins.